secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001104659-23-088390
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva receives Nasdaq notice for audit committee non-compliance after director resignation
--------------------------------------------------------------------------------

- Nasdaq notified Innoviva on Aug 2, 2023, that Audit Committee has only 2 independent directors after Dr. Deborah L. Birx resigned July 10.
- Company has cure period until the earlier of next annual meeting or July 10, 2024 to regain compliance with Nasdaq Rule 5605.
- No immediate impact on Nasdaq listing or common stock trading.
- Board is evaluating committee composition and intends to comply fully before cure period ends.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465923088390/0001104659-23-088390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465923088390/tm2323042d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer